Article
Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model
Registro en:
TEVA, A. et al. Responses of Leishmania (Viannia) braziliensis Cutaneous Infection to N-Methylglucamine Antimoniate in the Rhesus Monkey (Macaca mulatta) Model. J. Parasitol., v.91, n,4, p.976–978, Aug. 2005.
0022-3395
10.1645/GE-3486RN.1
1937-2345
Autor
Teva, A.
Porrozzi, R.
Oliveira Neto, M. P.
Grimaldi Jr., Gabriel
Resumen
The antileishmanial efficacy of the reference drug N-methylglucamine antimoniate (Glucantime) was evaluated in groups of rhesus monkeys with acute and chronic Leishmania (Viannia) braziliensis cutaneous infection. The therapeutic responses in experimental animals to either a low dose (5 mg/kg body wt/day for 28 days) or a routine dose (20 mg/kg/day for 28 days) of pentavalent antimony were similar to those reported in the human disease. Primates were cured of their lesions after treatment, but with cryptic parasitism and/or relapse. The rhesus model of L. (V.) braziliensis cutaneous leishmaniasis therefore provides an additional resource for preclinical trials with newer drugs. 2030-01-01